Aerovate Therapeutics Inc

NASDAQ AVTE

Data sourced from iex and EODHD
Download Data

Aerovate Therapeutics Inc Depreciation and Amortization for the year ending December 31, 2023: USD 96.00 K

Aerovate Therapeutics Inc Depreciation and Amortization is USD 96.00 K for the year ending December 31, 2023, a 41.18% change year over year. Depreciation and Amortization involve the systematic allocation of the cost of tangible and intangible assets over their useful lives.
  • Aerovate Therapeutics Inc Depreciation and Amortization for the year ending December 31, 2022 was USD 68.00 K, a 353.33% change year over year.
  • Aerovate Therapeutics Inc Depreciation and Amortization for the year ending December 31, 2021 was USD 15.00 K, a 1,400.00% change year over year.
  • Aerovate Therapeutics Inc Depreciation and Amortization for the year ending December 31, 2020 was USD 1.00 K, a 0.00% change year over year.
  • Aerovate Therapeutics Inc Depreciation and Amortization for the year ending December 31, 2019 was USD 1.00 K.
NASDAQ: AVTE

Aerovate Therapeutics Inc

CEO Mr. Timothy P. Noyes M.B.A.
IPO Date June 30, 2021
Location United States
Headquarters 930 Winter Street, Waltham, MA, United States, 02116
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email